Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | HSD17B3 | P37058 | 5/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | TDO2 | P48775 | 1/20 | 0.32 |
| ▸ | IDH1 | O75874 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23961966 | 0.89 | HSD17B3 (0.37) | KMT2AMEN1HSD17B3NOTUMSMN1; SMN2 | |
| SCHEMBL14887434 | 0.88 | HSD17B3 (0.50) | HSD17B3NOTUMSMN1; SMN2KDM4EHTT | |
| SCHEMBL14296207 | 0.87 | KMT2A (0.39) | KMT2AMEN1HSD17B3RIPK1NOTUM | |
| SCHEMBL25890671 | 0.87 | KMT2A (0.37) | KMT2AMEN1HSD17B3RIPK1NOTUM | |
| SCHEMBL21366311 | 0.86 | KMT2A (0.39) | KMT2AMEN1HSD17B3RIPK1NOTUM | |
| SCHEMBL26458710 | 0.86 | HSD17B3 (0.39) | KMT2AMEN1HSD17B3NOTUMSMN1; SMN2 | |
| SCHEMBL23961983 | 0.84 | NOTUM (0.35) | KMT2AMEN1HSD17B3NOTUMSMN1; SMN2 | |
| SCHEMBL24871031 | 0.84 | HSD17B3 (0.37) | HSD17B3NOTUMSMN1; SMN2KDM4EHTT | |
| SCHEMBL15958791 | 0.84 | KDM4E (0.50) | KMT2AMEN1HSD17B3NOTUMSMN1; SMN2 | |
| SCHEMBL21366027 | 0.84 | KMT2A (0.36) | KMT2AMEN1HSD17B3RIPK1NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11400165-B2 | Composition and method for modifying polypeptides | ADVANCED PROTEOME THERAPEUTICS INC. (US) | 2022-08-02 | — | — | US | disclosed |
| US-10280139-B2 | Cytotoxic peptides and conjugates thereof | NOVARTIS AG (CH) | 2019-05-07 | — | — | US | disclosed |
| US-20180155281-A1 | CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2018-06-07 | — | — | US | disclosed |
| US-20160311853-A1 | CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2016-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11400165-B2 | Composition and method for modifying polypeptides | PTMS, SRMS, ACP1 | KMT2A 1514/4885MEN1 1660/4885HSD17B3 4751/4885 |
| US-20160311853-A1 | CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF | CD47, NGLY1, VIP | KMT2A 4528/4885MEN1 1012/4885HSD17B3 3990/4885 |
| US-20180155281-A1 | CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF | CD47, MKI67, NGLY1 | KMT2A 4406/4885MEN1 687/4885HSD17B3 3981/4885 |
| US-10280139-B2 | Cytotoxic peptides and conjugates thereof | CD47, MKI67, NGLY1 | KMT2A 4406/4885MEN1 687/4885HSD17B3 3981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.